A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

Status
Active
Cancer Type
Kidney Cancer
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01693562
Protocol IDs
CD-ON-MEDI4736-1108 (primary)
Study Sponsor
MedImmune, Incorporated

Summary

This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced malignant melanoma, renal cell carcinoma, non-small cell lung cancer, or colorectal cancer followed by an expansion phase in subjects with advanced malignant melanoma, non-small cell lung cancer, or colorectal cancer.